Coherus Oncology (CHRS) Intangibles (2014 - 2026)

Coherus Oncology (CHRS) has 13 years of Intangibles data on file, last reported at $26.2 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 9.08% year-over-year to $26.2 million; the trailing twelve-month figure through Mar 2026 stood at $26.2 million (down 9.08% YoY), and the FY2025 full-year result was $26.2 million, down 9.08% from the prior year.
• Intangibles steadied at $26.2 million in Q1 2026, from $26.2 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $41.9 million in Q4 2023 to a low of $1.6 million in Q3 2025.
• A 5-year average of $22.5 million and a median of $26.2 million in 2025 frame the typical range for Intangibles.
• Across the five-year window, Intangibles soared 605.97% in 2023 and slumped 93.71% in 2025, its largest moves.
• Tracing CHRS's Intangibles over 5 years: stood at $5.9 million in 2022, then soared by 605.97% to $41.9 million in 2023, then slumped by 31.08% to $28.9 million in 2024, then dropped by 9.08% to $26.2 million in 2025, then changed by 0.0% to $26.2 million in 2026.
• Business Quant data shows CHRS's Intangibles at $26.2 million in Q1 2026, $26.2 million in Q4 2025, and $1.6 million in Q3 2025.